Detalhe da pesquisa
1.
Update on new treatments for rare ovarian tumours.
Curr Opin Obstet Gynecol
; 35(1): 27-33, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36440753
2.
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer.
Lancet Oncol
; 23(5): 557-558, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405086
3.
[Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey]. / Déficit de la recombinaison homologue dans les cancers épithéliaux de l'ovaire : de la caractérisation moléculaire au parcours des patientes.
Bull Cancer
; 110(4): 371-381, 2023 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-36863920
4.
Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?
Cancers (Basel)
; 15(14)2023 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509219
5.
[Tertiary lymphoid structures in cancer: From biology to therapeutic guides]. / Structures lymphoïdes tertiaires : de la biogenèse à l'impact thérapeutique en cancérologie.
Bull Cancer
; 110(6): 657-664, 2023 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-37150731
6.
[Combination strategies for checkpoint inhibition: Current practices and perspectives]. / Combinaisons d'inhibiteurs de points de contrôle immunitaires en oncologie : état de l'art et perspectives.
Bull Cancer
; 110(7-8): 790-801, 2023.
Artigo
em Francês
| MEDLINE | ID: mdl-37055309
7.
[Treatments for rare ovarian tumors: What's new?] / Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes.
Bull Cancer
; 110(7-8): 818-824, 2023.
Artigo
em Francês
| MEDLINE | ID: mdl-37045734
8.
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
Cancers (Basel)
; 14(4)2022 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205846
9.
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.
Cancers (Basel)
; 14(5)2022 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267439
10.
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Anticancer Res
; 42(1): 185-193, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969724
11.
[Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?] / Combinaison de la chirurgie et du traitement médical du cancer de l'ovaire : y a-t-il une stratégie optimale ?
Bull Cancer
; 109(2): 197-215, 2022 Feb.
Artigo
em Francês
| MEDLINE | ID: mdl-35027164
12.
Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management.
Front Oncol
; 12: 967479, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36059658
13.
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
Cancers (Basel)
; 14(16)2022 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36011033
14.
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
J Pers Med
; 12(10)2022 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36294734
15.
Cancer-Related Alopecia: From Etiologies to Global Management.
Cancers (Basel)
; 13(21)2021 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34771716
16.
[Alopecia and cancers: From basics to clinical practice]. / Alopécie et cancers : de la physiopathologie à la pratique clinique.
Bull Cancer
; 108(10): 963-980, 2021 Oct.
Artigo
em Francês
| MEDLINE | ID: mdl-34304865
17.
Loss of Apc Rapidly Impairs DNA Methylation Programs and Cell Fate Decisions in Lgr5+ Intestinal Stem Cells.
Cancer Res
; 80(11): 2101-2113, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213541
18.
[Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy]. / Ivosidénib pour le traitement des cholangiocarcinomes avec une mutation IDH1 R132 préalablement traités.
Bull Cancer
; 110(12): 1230-1231, 2023 12.
Artigo
em Francês
| MEDLINE | ID: mdl-37704495
19.
The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile?
Ann Transl Med
; 11(11): 393, 2023 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37970606
20.
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]. / Nouvelle AMM européenne : pembrolizumab en association à la chimiothérapie en première ligne des carcinomes épidermoïdes de l'Åsophage ou des adénocarcinomes de la jonction Åsogastrique HER2-négatifs non résécables/métastatiques et présentant une expression de PDL1 avec un CPS≥10.
Bull Cancer
; 109(2): 111-113, 2022 02.
Artigo
em Francês
| MEDLINE | ID: mdl-34998526